{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:56:08Z","timestamp":1791924968730,"version":"4.3.4"},"reference-count":54,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Perritt Charitable Foundation"},{"name":"Burgess Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: High-grade serous ovarian cancer (HGSOC) is usually discovered in advanced stages and often relapses shortly after initial conventional therapy. Survival in HGSOC patients might be improved with the use of novel immune therapies, which potentiate autologous anti-tumor responses. Dendritic cells (DCs) are potent antigen-presenting cells that can initiate immune responses, activate cytotoxic T cells and drive T-cell differentiation. This pilot trial evaluated the safety and efficacy of a unique DC vaccine (\u03b1-DC-1) in relapsed, advanced HGSOC patients with minimal tumor burden. Methods: Monocytes from patient leukaphereses were used to propagate a unique autologous DC, the \u03b1-DC-1, generated with granulocyte\u2013macrophage colony-stimulating factor and interleukin-4, pulsed with keyhole limpet hemocyanin (KLH) and tumor lysate (from debulking surgery) on day 5, and matured with a cocktail of cytokines and chemokines on day 6. Mature \u03b1-DC-1 were harvested on day 7 and administered intranodally (inguinal nodes) every other week for three doses\/cycle for up to three DC vaccine cycles (nine vaccines). The primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: In 19 patients treated, the median PFS was 9.7 months (95% CI: (5, NA)) and the median OS was 42.2 months (95% CI: (31.2, 68.3)). In 5\/19 (26.3%) patients, OS exceeded five years. Administration of six or more vaccines was associated with a significant improvement in PFS. No grade 2 or higher toxicities were noted. Conclusions: Our \u03b1-DC-1 vaccine was safe, and 94.2% elicited an immune response to KLH. The long OS, exceeding 5 years in some patients, suggests this DC vaccine may improve survival for some with relapsed HGSOC.<\/jats:p>","DOI":"10.3390\/cancers18081285","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:15:08Z","timestamp":1776669308000},"page":"1285","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of an Alpha-DC-1 Dendritic Cell-Based Vaccine Clinical Trial in Patients with Low-Tumor-Burden High-Risk Ovarian Carcinoma"],"prefix":"10.3390","volume":"18","author":[{"given":"Patrick J.","family":"Stiff","sequence":"first","affiliation":[{"name":"Department of Medicine, Cardinal Bernardin Cancer Center, Stritch School of Medicine, Loyola University Chicago, Building 112, 2160 South First Avenue, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3345-6912","authenticated-orcid":false,"given":"Cheryl M.","family":"Czerlanis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardinal Bernardin Cancer Center, Stritch School of Medicine, Loyola University Chicago, Building 112, 2160 South First Avenue, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald K.","family":"Potkul","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Liotta","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yu","sequence":"additional","affiliation":[{"name":"Cellular Therapy Center, Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Pease","sequence":"additional","affiliation":[{"name":"Cellular Therapy Center, Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2941-3821","authenticated-orcid":false,"given":"Swarnali","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Center for Data Science and Consulting, Department of Mathematics and Statistics, Loyola University Chicago, Chicago, IL 60660, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Mehrotra","sequence":"additional","affiliation":[{"name":"Department of Pathology, Loyola University Medical Center, Building 110, 2160 South First Avenue, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Winder","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Guevara","sequence":"additional","affiliation":[{"name":"Cancer Clinical Trials Office, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Palmer","sequence":"additional","affiliation":[{"name":"Cancer Clinical Trials Office, Cardinal Bernardin Cancer Center, Loyola University Chicago, 2160 South First Avenue, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen L.","family":"Drakes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cardinal Bernardin Cancer Center, Stritch School of Medicine, Loyola University Chicago, Building 112, 2160 South First Avenue, Maywood, IL 60153, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"ref_1","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2020.07.008","article-title":"Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990\u20132017","volume":"159","author":"Zheng","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e26849","DOI":"10.1097\/MD.0000000000026849","article-title":"Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer: A systematic review and meta-analysis","volume":"100","author":"Liu","year":"2021","journal-title":"Medicine"},{"key":"ref_4","first-page":"280","article-title":"Epithelial ovarian cancer: Evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","first-page":"100629","article-title":"Epithelial ovarian cancer: Review article","volume":"33","author":"Sambasivan","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12032-017-0960-z","article-title":"A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer","volume":"34","author":"Oronsky","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): An open-label, randomised, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"Lancet"},{"key":"ref_9","first-page":"103","article-title":"Immune Checkpoint Inhibitors in the Treatment of Cancer","volume":"17","author":"Zam","year":"2022","journal-title":"Curr. Rev. Clin. Exp. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Vaddepally, R.K., Kharel, P., Pandey, R., Garje, R., and Chandra, A.B. (2020). Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers, 12.","DOI":"10.3390\/cancers12030738"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood.V25.2.179.179","article-title":"Successful allogenic bone marrow transplantation in man: Chimerism, induced specific tolerance, and possible anti-leukemic effects","volume":"25","author":"Amiel","year":"1965","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13048-021-00862-5","article-title":"Efficacy of PD-1\/PD-L1 inhibitors in ovarian cancer: A single-arm meta-analysis","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Ovarian Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Dumitru, A., Dobrica, E.C., Croitoru, A., Cretoiu, S.M., and Gaspar, B.S. (2022). Focus on PD-1\/PD-L1 as a Therapeutic Target in Ovarian Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012067"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Walsh, C.S., Kamrava, M., Rogatko, A., Kim, S., Li, A., Cass, I., Karlan, B., and Rimel, B.J. (2021). Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0252665"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/intimm\/dxw020","article-title":"Immune checkpoint inhibition in ovarian cancer","volume":"28","author":"Hamanishi","year":"2016","journal-title":"Int. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e002873","DOI":"10.1136\/jitc-2021-002873","article-title":"Immunological configuration of ovarian carcinoma: Features and impact on disease outcome","volume":"9","author":"Fucikova","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yang, Y., Yang, Y., Yang, J., Zhao, X., and Wei, X. (2020). Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00758"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S1582","DOI":"10.1016\/j.annonc.2025.09.049","article-title":"LBA3 Pembrolizumab vs placebo plus weekly paclitaxel \u00b1 bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65\/KEYNOTE-B96 study","volume":"36","author":"Colombo","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e70455","DOI":"10.1002\/mco2.70455","article-title":"Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential","volume":"6","author":"Jin","year":"2025","journal-title":"MedComm"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","article-title":"Immunobiology of dendritic cells","volume":"18","author":"Banchereau","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/IGC.0b013e3181bb70c6","article-title":"Ovarian cancer cells induce peripheral mature dendritic cells to differentiate into macrophagelike cells in vitro","volume":"19","author":"Chen","year":"2009","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1084\/jem.20111413","article-title":"Ovarian cancer progression is controlled by phenotypic changes in dendritic cells","volume":"209","author":"Scarlett","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/cac2.12596","article-title":"Dysfunction of dendritic cells in tumor microenvironment and immunotherapy","volume":"44","author":"Chen","year":"2024","journal-title":"Cancer Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101481","DOI":"10.1016\/j.smim.2021.101481","article-title":"The role of dendritic cells in cancer and anti-tumor immunity","volume":"52","author":"Marciscano","year":"2021","journal-title":"Semin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e003190","DOI":"10.1136\/jitc-2021-003190","article-title":"Safety and efficacy of dendritic cell-based immunotherapy DCVAC\/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: A phase 2, open-label, multicenter, randomized trial","volume":"10","author":"Rob","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2412876","DOI":"10.1080\/2162402X.2024.2412876","article-title":"Trial watch: Anticancer vaccination with dendritic cells","volume":"13","author":"Borges","year":"2024","journal-title":"Oncoimmunology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00262-001-0255-1","article-title":"Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: Clinical and immunological evaluation of a phase I trial","volume":"51","author":"Hernando","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"eaao5931","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1479-5876-11-149","article-title":"3693890; A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer","volume":"11","author":"Kandalaft","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Zhang, X., He, T., Li, Y., Chen, L., Liu, H., Wu, Y., and Guo, H. (2020). Dendritic Cell Vaccines in Ovarian Cancer. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.613773"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.1158\/0008-5472.CAN-04-1261","article-title":"Alpha-type-1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity","volume":"64","author":"Mailliard","year":"2004","journal-title":"Cancer Res."},{"key":"ref_36","first-page":"641","article-title":"Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity","volume":"61","author":"Lambert","year":"2001","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1172\/JCI6909","article-title":"Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells","volume":"104","author":"Dhodapkar","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00262-012-1263-z","article-title":"Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters","volume":"61","author":"Aarntzen","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/era.12.153","article-title":"Dendritic cell immunotherapy in ovarian cancer","volume":"13","author":"Stiff","year":"2013","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jid.2020.12.008","article-title":"Research Techniques Made Simple: Use of Imaging Mass Cytometry for Dermatological Research and Clinical Applications","volume":"141","author":"Veenstra","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pbiomolbio.2022.10.003","article-title":"Imaging mass cytometry: High-dimensional and single-cell perspectives on the microenvironment of solid tumours","volume":"175","author":"Liu","year":"2022","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"ref_44","unstructured":"The R Core Team (2025). A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: https:\/\/www.r-project.org\/."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Brandum, E.P., J\u00f8rgensen, A.S., Rosenkilde, M.M., and Hjort\u00f8, G.M. (2021). Dendritic Cells and CCR7 Expression: An Important Factor for Autoimmune Diseases, Chronic Inflammation, and Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158340"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/15384047.2015.1040960","article-title":"Tumor infiltrating lymphocytes in ovarian cancer","volume":"16","author":"Santoiemma","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: Impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e173290","DOI":"10.1001\/jamaoncol.2017.3290","article-title":"Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer","volume":"3","author":"Goode","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_51","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1189\/jlb.1107737","article-title":"Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia","volume":"84","author":"Lee","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.21873\/anticanres.14669","article-title":"Alpha-type-1 Polarized Dendritic Cell-based Vaccination in Newly Diagnosed High-grade Glioma: A Phase II Clinical Trial","volume":"40","author":"Mitsuya","year":"2020","journal-title":"Anticancer. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/8\/1285\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:29:47Z","timestamp":1776670187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/8\/1285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["cancers18081285"],"URL":"https:\/\/doi.org\/10.3390\/cancers18081285","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]}}}